TsRNA-49-73-Glu-CTC: A promising serum biomarker in non-small cell lung cancer.

IF 2.6 3区 综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES
PLoS ONE Pub Date : 2025-03-28 eCollection Date: 2025-01-01 DOI:10.1371/journal.pone.0320187
Chenyu Li, Shenjie Zhong, Juan Chen, Xiaofeng Mu
{"title":"TsRNA-49-73-Glu-CTC: A promising serum biomarker in non-small cell lung cancer.","authors":"Chenyu Li, Shenjie Zhong, Juan Chen, Xiaofeng Mu","doi":"10.1371/journal.pone.0320187","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Lung cancer has the highest incidence and mortality rates globally, with the majority of cases classified as non-small cell lung cancer (NSCLC). Due to the absence of specific tumor biomarkers, most lung cancer cases are diagnosed at an advanced stage. Therefore, the identification of novel molecular biomarkers with high sensitivity and specificity for early diagnosis is deemed crucial for enhancing the treatment of NSCLC. Transfer RNA-derived small RNA (tsRNA) is closely associated with malignant tumors and holds promise as a potential biomarker for tumor diagnosis. This study aimed to investigate whether serum tsRNA could serve as a biomarker for NSCLC.</p><p><strong>Methods: </strong>Differentially expressed tsRNAs were identified through high-throughput sequencing of serum samples obtained from patients with NSCLC and healthy individuals. Additional serum samples were collected for validation using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). The diagnostic performance of these tsRNAs was assessed through Receiver Operating Characteristic (ROC) Curve Analysis. Furthermore, preliminary functional exploration was undertaken through cell experiments.</p><p><strong>Results: </strong>tsRNA-49-73-Glu-CTC is highly expressed in the serum of patients with NSCLC and demonstrates superior diagnostic value compared to commonly used tumor markers in clinical practice, such as Carcinoembryonic Antigen (CEA), Neuron-Specific Enolase (NSE), and Cytokeratin 19 Fragment (CYFRA). A combined diagnostic approach enhances the accuracy of NSCLC detection. Additionally, tsRNA-49-73-Glu-CTC is highly expressed in A549 cells, and transfection with a tsRNA-49-73-Glu-CTC inhibitor significantly reduces both proliferation and migration capabilities.</p><p><strong>Conclusions: </strong>tsRNA-49-73-Glu-CTC has the potential to serve as a novel molecular diagnostic biomarker for NSCLC and plays a significant role in the biological processes associated with NSCLC proliferation and migration.</p>","PeriodicalId":20189,"journal":{"name":"PLoS ONE","volume":"20 3","pages":"e0320187"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952254/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PLoS ONE","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1371/journal.pone.0320187","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Lung cancer has the highest incidence and mortality rates globally, with the majority of cases classified as non-small cell lung cancer (NSCLC). Due to the absence of specific tumor biomarkers, most lung cancer cases are diagnosed at an advanced stage. Therefore, the identification of novel molecular biomarkers with high sensitivity and specificity for early diagnosis is deemed crucial for enhancing the treatment of NSCLC. Transfer RNA-derived small RNA (tsRNA) is closely associated with malignant tumors and holds promise as a potential biomarker for tumor diagnosis. This study aimed to investigate whether serum tsRNA could serve as a biomarker for NSCLC.

Methods: Differentially expressed tsRNAs were identified through high-throughput sequencing of serum samples obtained from patients with NSCLC and healthy individuals. Additional serum samples were collected for validation using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). The diagnostic performance of these tsRNAs was assessed through Receiver Operating Characteristic (ROC) Curve Analysis. Furthermore, preliminary functional exploration was undertaken through cell experiments.

Results: tsRNA-49-73-Glu-CTC is highly expressed in the serum of patients with NSCLC and demonstrates superior diagnostic value compared to commonly used tumor markers in clinical practice, such as Carcinoembryonic Antigen (CEA), Neuron-Specific Enolase (NSE), and Cytokeratin 19 Fragment (CYFRA). A combined diagnostic approach enhances the accuracy of NSCLC detection. Additionally, tsRNA-49-73-Glu-CTC is highly expressed in A549 cells, and transfection with a tsRNA-49-73-Glu-CTC inhibitor significantly reduces both proliferation and migration capabilities.

Conclusions: tsRNA-49-73-Glu-CTC has the potential to serve as a novel molecular diagnostic biomarker for NSCLC and plays a significant role in the biological processes associated with NSCLC proliferation and migration.

Abstract Image

Abstract Image

Abstract Image

TsRNA-49-73-Glu-CTC:一种有前景的非小细胞肺癌血清生物标志物
目的:肺癌是全球发病率和死亡率最高的疾病,大多数病例属于非小细胞肺癌(NSCLC)。由于缺乏特异性的肿瘤生物标志物,大多数肺癌病例在晚期被诊断出来。因此,鉴别出具有高敏感性和特异性的新型分子生物标志物进行早期诊断对于加强对NSCLC的治疗至关重要。转移RNA衍生的小RNA (tsRNA)与恶性肿瘤密切相关,有望成为肿瘤诊断的潜在生物标志物。本研究旨在探讨血清tsRNA是否可以作为非小细胞肺癌的生物标志物。方法:通过对非小细胞肺癌患者和健康个体的血清样本进行高通量测序,鉴定差异表达的tsRNAs。另外收集血清样本进行反转录定量聚合酶链反应(RT-qPCR)验证。通过受试者工作特征(ROC)曲线分析评估这些tsRNAs的诊断性能。此外,通过细胞实验进行了初步的功能探索。结果:tsRNA-49-73-Glu-CTC在NSCLC患者血清中高表达,与临床常用的肿瘤标志物如癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)、细胞角蛋白19片段(CYFRA)相比,tsRNA-49-73-Glu-CTC具有更高的诊断价值。联合诊断方法提高了非小细胞肺癌检测的准确性。此外,tsRNA-49-73-Glu-CTC在A549细胞中高表达,转染tsRNA-49-73-Glu-CTC抑制剂可显著降低A549细胞的增殖和迁移能力。结论:tsRNA-49-73-Glu-CTC有潜力作为一种新的NSCLC分子诊断生物标志物,并在NSCLC增殖和迁移相关的生物学过程中发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PLoS ONE
PLoS ONE 生物-生物学
CiteScore
6.20
自引率
5.40%
发文量
14242
审稿时长
3.7 months
期刊介绍: PLOS ONE is an international, peer-reviewed, open-access, online publication. PLOS ONE welcomes reports on primary research from any scientific discipline. It provides: * Open-access—freely accessible online, authors retain copyright * Fast publication times * Peer review by expert, practicing researchers * Post-publication tools to indicate quality and impact * Community-based dialogue on articles * Worldwide media coverage
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信